Go to content
UR Home

Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

Yakoub-Agha, Ibrahim ; Chabannon, Christian ; Bader, Peter ; Basak, Grzegorz W. ; Bonig, Halvard ; Ciceri, Fabio ; Corbacioglu, Selim ; Duarte, Rafael F. ; Einsele, Hermann ; Hudecek, Michael ; Kersten, Marie José ; Köhl, Ulrike ; Kuball, Jürgen ; Mielke, Stephan ; Mohty, Mohamad ; Murray, John ; Nagler, Arnon ; Robinson, Stephen ; Saccardi, Riccardo ; Sanchez-Guijo, Fermin ; Snowden, John A. ; Srour, Micha ; Styczynski, Jan ; Urbano-Ispizua, Alvaro ; Hayden, Patrick J. ; Kröger, Nicolaus


Chimeric antigen receptor (CAR) T cells are a novel class of anti-cancer therapy in which autologous or allogeneic T cells are engineered to express a CAR targeting a membrane antigen. In Europe, tisagen-lecleucel (Kymriah (TM)) is approved for the treatment of refractory/relapsed acute lymphoblastic leukemia in children and young adults as well as relapsed/refractory diffuse large B-cell ...


Owner only: item control page
  1. Homepage UR

University Library

Publication Server


Publishing: oa@ur.de
0941 943 -4239 or -69394

Dissertations: dissertationen@ur.de
0941 943 -3904

Research data: datahub@ur.de
0941 943 -5707

Contact persons